Evidence mapPaperPMID 33801799Full record

ReviewLife (Basel, Switzerland)2021

Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks.

Doris Rusic, Marino Vilovic, Josipa Bukic, Dario Leskur, Ana Seselja Perisin, Marko Kumric, Dinko Martinovic, Ana Petric, Darko Modun, Josko Bozic

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Antimicrobial Investigation of Phthalimide andLife (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Antimicrobial Resistance inMicroorganisms · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Doris RusicDepartment of Pharmacy, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.ORCID 0000-0002-7018-4947
Marino VilovicDepartment of Pathophysiology, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.
Josipa BukicDepartment of Pharmacy, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.ORCID 0000-0002-9316-5538
Dario LeskurDepartment of Pharmacy, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.ORCID 0000-0002-5126-3869
Ana Seselja PerisinDepartment of Pharmacy, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.ORCID 0000-0001-7927-5311
Marko KumricDepartment of Pathophysiology, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.ORCID 0000-0002-9696-3359
Dinko MartinovicDepartment of Pathophysiology, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.
Ana PetricDepartment of Pharmacy, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.
Darko ModunDepartment of Pharmacy, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.
Josko BozicDepartment of Pathophysiology, University of Split School of Medicine, Soltanska 2, 21 000 Split, Croatia.ORCID 0000-0003-1634-0635
University of Split · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The net effect of the coronavirus disease 2019 (COVID-19) pandemic and the response to it on the emergence of antimicrobial resistance is yet unknown. Positive impacts on the spread of multiresistant pathogens and infections in general may be observed with the implementation of general preventative measures for the spread of infectious disease such as social distancing, reduced travel and increased personal hygiene. This pandemic has accelerated the development of novel technologies, such as mRNA vaccines, that may be used to fight other diseases. These should be capitalized upon to manage the ongoing antimicrobial resistance pandemic in the background. However, it is likely that the COVID-19 pandemic is fueling the emergence of antimicrobial resistance due to high rates of inappropriate antimicrobial prescribing, the high use of biocides and the interruption of treatment for other conditions. Clinical uncertainty driven by the lack of effective diagnostics and practice of telemedicine may have driven the inappropriate use of antimicrobials. As pathogens know no borders, increased focus is needed for infectious diseases still threatening low- and middle-income countries such as tuberculosis. Stewardship measures for future outbreaks should stress the importance of social distancing and hand washing but discourage the overuse of disinfectants and antimicrobials that are not proven effective.

Indexed as

antibioticsantimicrobial resistancebiocidecoronavirusCOVID-19disinfectionICU

Identifiers

PMID33801799
PMCPMC8000815
OpenAlexW3135881705

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.